Pharmacyte Biotech Inc (OTCMKTS:PMCB) What To Expect?

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is one of those rare companies that have stayed stable recently in the stock market. The company is amongst those clinical stage organizations, which mostly works on treatments for diabetes and cancer. In comparison to its competitors, the company has three medical trial treatments ready, where most have one. This is the reason that many investors believe that the company might move to the next level by the end of this year. Currently, the stock has held stable at $0.138, hardly fluctuating above 1%.

It is projected that the initiation of each trial will give the stable stock a boost and a successful event could mean that it might grow too large to be counted as a penny stock. Subsequently, there is always the looming danger of failure of the event, which would then cause the stock to start crashing. In which case, the company would have to make sure that the remaining two events are a success. The added pressure may cause the company to underperform or even delay the other events, which would mean the crash worsens. There is little need to worry though, since the initial tests have shown promise and would be moved further after proper inspection of the subjects.

The most highly anticipated event is the one to be held in Australia, where the company’s treatment for pancreatic cancer is to be tested against the best chemotherapy methods. The results would be highly influential in deciding the company’s value. The remaining two events would be conducted in the US. These would also concentrate on pancreatic cancer, the pain associated with it and the accretion of fluids due to the disease.

We would still have to wait and see if the company rolls out any plans for treatment with diabetes, to further gain investor interest. However, it is highly doubtful that a penny stock company would have the finances to pull off any more successful events. For most traders, the message would be to await the results of the first trial.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 All RIGHTS RESERVED.